晚期不可切除黑色素瘤达到CR、PR或SD患者停止免疫检查点抑制

IF 4.4 3区 医学 Q2 ONCOLOGY
Anna M Czarnecka, Paweł Teterycz, Krzysztof Ostaszewski, Piotr Błoński, Magdalena Zielińska, Łukasz Galus, Robert Dziura, Natasza Kempa-Kamińska, Katarzyna Galwas, Bożena Cybulska-Stopa, Jacek Mackiewicz, Marcin Ziętek, Grażyna Kamińska-Winciorek, Katarzyna Kozak, Piotr Rutkowski
{"title":"晚期不可切除黑色素瘤达到CR、PR或SD患者停止免疫检查点抑制","authors":"Anna M Czarnecka, Paweł Teterycz, Krzysztof Ostaszewski, Piotr Błoński, Magdalena Zielińska, Łukasz Galus, Robert Dziura, Natasza Kempa-Kamińska, Katarzyna Galwas, Bożena Cybulska-Stopa, Jacek Mackiewicz, Marcin Ziętek, Grażyna Kamińska-Winciorek, Katarzyna Kozak, Piotr Rutkowski","doi":"10.1007/s11523-025-01156-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The optimal duration of immunotherapy (ITH) remains undefined for patients with metastatic melanoma, and debates on de-escalation strategies are ongoing. Patients in the pivotal KEYNOTE and CheckMate trials who experienced a complete response (CR) on ITH had long-term responses, even after treatment was terminated early because of toxicity or at the physician's discretion.</p><p><strong>Objective: </strong>Our study explores the duration of planned ITH drug holidays-intentional ITH suspension until disease progression off treatment-in patients with unresectable and metastatic melanoma treated for at least 6 months with ITH.</p><p><strong>Patients and methods: </strong>We enrolled 222 patients who received anti-programmed cell death protein-1-based ITH, experienced stable disease, partial response, or complete response during ITH, and had no treatment-limiting toxicities.</p><p><strong>Results: </strong>At a median follow-up of 63 months since the first ITH cycle, median overall survival after the drug holiday start (OS3) was not reached, and the 5-year OS3 rate was 79.3%. Median progression-free survival since the start of drug holiday (PFS3) was not reached, with a 3-year PFS3 rate of 65% for all patients, and the highest rate was in the complete response group (72.3%). After the drug holidays, upon disease progression off treatment, the objective response rate to ITH reintroduction was 58.9%. Again, durable, ongoing objective responses were achieved on ITH reintroduction after drug holidays. The best radiological response achieved before drug holidays correlated with the duration of ITH drug holidays, with the longest duration of disease control without treatment for complete responders.</p><p><strong>Conclusions: </strong>Drug holidays in patients with unresectable and metastatic melanoma after an objective response or prolonged disease stabilization during ITH result in durable control of the disease, particularly in patients with complete response.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD.\",\"authors\":\"Anna M Czarnecka, Paweł Teterycz, Krzysztof Ostaszewski, Piotr Błoński, Magdalena Zielińska, Łukasz Galus, Robert Dziura, Natasza Kempa-Kamińska, Katarzyna Galwas, Bożena Cybulska-Stopa, Jacek Mackiewicz, Marcin Ziętek, Grażyna Kamińska-Winciorek, Katarzyna Kozak, Piotr Rutkowski\",\"doi\":\"10.1007/s11523-025-01156-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The optimal duration of immunotherapy (ITH) remains undefined for patients with metastatic melanoma, and debates on de-escalation strategies are ongoing. Patients in the pivotal KEYNOTE and CheckMate trials who experienced a complete response (CR) on ITH had long-term responses, even after treatment was terminated early because of toxicity or at the physician's discretion.</p><p><strong>Objective: </strong>Our study explores the duration of planned ITH drug holidays-intentional ITH suspension until disease progression off treatment-in patients with unresectable and metastatic melanoma treated for at least 6 months with ITH.</p><p><strong>Patients and methods: </strong>We enrolled 222 patients who received anti-programmed cell death protein-1-based ITH, experienced stable disease, partial response, or complete response during ITH, and had no treatment-limiting toxicities.</p><p><strong>Results: </strong>At a median follow-up of 63 months since the first ITH cycle, median overall survival after the drug holiday start (OS3) was not reached, and the 5-year OS3 rate was 79.3%. Median progression-free survival since the start of drug holiday (PFS3) was not reached, with a 3-year PFS3 rate of 65% for all patients, and the highest rate was in the complete response group (72.3%). After the drug holidays, upon disease progression off treatment, the objective response rate to ITH reintroduction was 58.9%. Again, durable, ongoing objective responses were achieved on ITH reintroduction after drug holidays. The best radiological response achieved before drug holidays correlated with the duration of ITH drug holidays, with the longest duration of disease control without treatment for complete responders.</p><p><strong>Conclusions: </strong>Drug holidays in patients with unresectable and metastatic melanoma after an objective response or prolonged disease stabilization during ITH result in durable control of the disease, particularly in patients with complete response.</p>\",\"PeriodicalId\":22195,\"journal\":{\"name\":\"Targeted Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Targeted Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11523-025-01156-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Targeted Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11523-025-01156-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:对于转移性黑色素瘤患者,免疫治疗(ITH)的最佳持续时间仍未确定,并且关于降级策略的争论正在进行中。在关键性的KEYNOTE和CheckMate试验中,即使在由于毒性或医生的判断而提前终止治疗后,在ITH上经历完全缓解(CR)的患者也有长期的缓解。目的:我们的研究探讨了不可切除和转移性黑色素瘤患者接受ITH治疗至少6个月的计划ITH药物假期的持续时间-故意暂停ITH直到疾病进展停止治疗。患者和方法:我们招募了222例患者,他们接受了基于抗程序性细胞死亡蛋白1的ITH,在ITH期间经历了疾病稳定、部分缓解或完全缓解,并且没有治疗限制性毒性。结果:自第一个ITH周期开始的中位随访时间为63个月,药物假期开始后的中位总生存率(OS3)未达到,5年OS3率为79.3%。自药物假期开始(PFS3)以来的中位无进展生存期未达到,所有患者的3年PFS3率为65%,完全缓解组的发生率最高(72.3%)。药物假期后,疾病进展停止治疗后,ITH重新引入的客观有效率为58.9%。再次,持久的,持续的客观反应是在药物假期后重新引入ITH。在药物假期前获得的最佳放射反应与ITH药物假期的持续时间相关,完全缓解者的疾病控制时间最长。结论:不可切除和转移性黑色素瘤患者在客观缓解或ITH期间延长疾病稳定后的药物假期可导致疾病的持久控制,特别是完全缓解的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD.

Background: The optimal duration of immunotherapy (ITH) remains undefined for patients with metastatic melanoma, and debates on de-escalation strategies are ongoing. Patients in the pivotal KEYNOTE and CheckMate trials who experienced a complete response (CR) on ITH had long-term responses, even after treatment was terminated early because of toxicity or at the physician's discretion.

Objective: Our study explores the duration of planned ITH drug holidays-intentional ITH suspension until disease progression off treatment-in patients with unresectable and metastatic melanoma treated for at least 6 months with ITH.

Patients and methods: We enrolled 222 patients who received anti-programmed cell death protein-1-based ITH, experienced stable disease, partial response, or complete response during ITH, and had no treatment-limiting toxicities.

Results: At a median follow-up of 63 months since the first ITH cycle, median overall survival after the drug holiday start (OS3) was not reached, and the 5-year OS3 rate was 79.3%. Median progression-free survival since the start of drug holiday (PFS3) was not reached, with a 3-year PFS3 rate of 65% for all patients, and the highest rate was in the complete response group (72.3%). After the drug holidays, upon disease progression off treatment, the objective response rate to ITH reintroduction was 58.9%. Again, durable, ongoing objective responses were achieved on ITH reintroduction after drug holidays. The best radiological response achieved before drug holidays correlated with the duration of ITH drug holidays, with the longest duration of disease control without treatment for complete responders.

Conclusions: Drug holidays in patients with unresectable and metastatic melanoma after an objective response or prolonged disease stabilization during ITH result in durable control of the disease, particularly in patients with complete response.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Targeted Oncology
Targeted Oncology 医学-肿瘤学
CiteScore
8.40
自引率
3.70%
发文量
64
审稿时长
>12 weeks
期刊介绍: Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes: Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches. Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways. Current Opinion articles that place interesting areas in perspective. Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations. Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement. Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信